In many diseases, components of the ubiquitin system -such as E2/E3 ligases and deubiquitylases -are dysregulated. The ubiquitin system has therefore become an emergent 30 target for the treatment of a number of diseases, including cancer, neurodegeneration and autoimmunity. Despite of the efforts in this field, primary screenings of compound libraries to individuate new potential therapeutic molecules targeting the ubiquitin pathway have been strongly limited by the lack of robust and fast high-throughput assays. Here we report the first label-free high-throughput screening (HTS) assay for ubiquitin E2 conjugating enzymes and 35 E3 ligases based on Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI TOF) mass spectrometry. The MALDI TOF E2/E3 assay allows us to test E2 conjugating enzymes and E3 ligases for their ubiquitin transfer activity, to identify E2/E3 active pairs, inhibitor potency and specificity and to screen compound libraries in vitro without synthesis of chemical or fluorescent probes. We demonstrate that the MALDI TOF E2/E3 assay is a universal tool 40 for drug discovery screening in the ubiquitin pathway as it is suitable for working with all E3 ligase families and requires a reduced amount of reagents, compared to standard biochemical assays.
Introduction 45
Ubiquitylation is a post-translational modification which impacts almost every biological process in the cell. Dysregulation of the ubiquitylation pathway is associated with several diseases, including cancer, neurodegenerative disorders and immunological dysfunctions.
Single ubiquitin moieties or polyubiquitin chains are added to the substrate by the combined action of three different classes of enzymes: the E1 activating enzymes, the E2s conjugating 50 enzymes and the E3 ligase enzymes 1 . In the first step, a single ubiquitin molecule is coupled to the active site of an E1 ubiquitin activating enzyme in an ATP-dependent reaction. In the second step, the ubiquitin molecule is transferred from E1 to an E2 ubiquitin conjugating enzyme. In the final step, ubiquitin is transferred to the protein substrate in a process mediated by an E3 ubiquitin ligase, which provides a binding platform for ubiquitin-charged E2 and the 55 substrate. Ubiquitin chain formation is highly specific and regulated by a plethora of different E2 conjugating enzymes and E3 ligases. The human genome encodes two ubiquitin-activating E1, >30 ubiquitin specific E2 and 600-700 E3 ligases 2 . Thus, including about 100 deubiquitylating enzymes, approximately 800 ubiquitin enzymes regulate the dynamic ubiquitylation of a wide range of protein substrates 2 . Within this complexity, E3 ligases are the 60 most diverse class of enzymes in the ubiquitylation pathway as they play a central role in determining the selectivity of ubiquitin-mediated protein degradation and signalling.
E3 ligases have been associated with a number of pathogenic mechanisms. Mutations in the E3 ligases MDM2, BRCA1, TRIMs and Parkin have been linked to multiple cancers and neurodegenerative diseases 3, 4, 5 and MDM2-p53 interaction inhibitors have already been 65 developed as potential anti-cancer treatment 6 . This highlights the potential of E2 enzymes and E3 ligases as drug targets. Although all E3 ligases are involved in the final step of covalent ubiquitylation of target proteins, they differ in both structure and mechanism and can be classified in three main families depending on the type of E3 ligases promoted ubiquitin-protein ligation and on the presence of characteristic domains. The Really Interesting New Genes 70 (RING) ligases bring the ubiquitin-E2 complex into the molecular vicinity of the substrate and facilitate ubiquitin transfer directly from the E2 enzyme to the substrate protein. In contrast, Homologous to the E6-AP C Terminus family (HECTs) covalently bind the ubiquitin via a cysteine residue in their catalytic HECT domain before shuttling it onto the target molecule.
RING between RINGs (RBRs) E3-ligases were shown to use both RING and HECT-like 75 mechanisms were ubiquitin is initially recruited on a RING domain (RING1) then transferred to the substrate through a conserved cysteine residue in a second RING domain. The vast majority of human E3 enzymes belong to the RING family, while only 28 belong to the HECT and 14 to the RBR family of E3 ligases 7 .
Due to the high attractiveness of E2 and E3 ligases as drug targets, a number of drug 80 discovery assays have been published, based on detection by fluorescence 8, 9, 10 , antibodies 11, 12, 13, 14 , tandem ubiquitin-binding entities (TUBEs) 15, 16 , surface plasmon resonance (SPR) 17 or cellular 18 and bacterial 19 two hybrid. However, many of these tools are either too expensive for very high-throughput drug discovery or potentially result in false-positive and false negative hits due to the use of non-physiological E2/E3 ligase substrates. We have addressed this gap 85 by developing the first in vitro label-free MALDI TOF mass spectrometry-based approach to screen the activity of E2 and E3 ligases that uses unmodified monoubiquitin as substrate. As a proof of concept, we screened a collection of 1443 FDA approved drugs for inhibitors of a subset of three E3 ligases that are clinically relevant and belong to three different E3 ligase families. The screen shows high reproducibility and robustness and we were able to identify a 90 subset of 15 molecules active against the E3 ligases tested. We validated the most powerful positive hits by determining the IC50 values against their targets, confirming that Bendamustine and Candesartan Cilexitel inhibit HOIP and MDM2, respectively, in in vitro conditions.
95

Results
MALDI TOF E2-E3 assay rational and development
E2 and E3 ligase activity results in formation of free or attached polyubiquitin chains, monoubiquitylation and/or multiple mono-ubiquitylation of a specific substrate. However, in absence of a specific substrate, most E3 ligases will either produce free polyubiquitin chains or undergo 100 auto-ubiquitylation which is a mechanism thought to be responsible for the regulation of the E3 enzyme itself 20 . Furthermore, there is some evidence that auto-ubiquitylation of E3 ligases is facilitating the recruitment of the E2 ubiquitin-conjugating enzyme 21 . Auto-ubiquitylation assays or free polyubiquitin chain production have been widely used to assess the E3 ligase potential of a protein 20, 22 . We used this property of E2 and E3 ligases to design a MALDI TOF 105 mass spectrometry-based high-throughput screening (HTS) method that allowed the reliable determination of activities of E2 and E3 ligase pairs by measuring the depleting intensity of mono-ubiquitin in the assay as a readout.
As proof-of-concept we used three E3 ligases belonging to different E3 families and representative of all the currently known ubiquitylation mechanisms. MDM2 is an RING-type 110 E3 ligase which controls the stability of the transcription factor p53, a key tumour suppressor that is often found mutated in human cancers 23, 24 . ITCH belongs to the HECT domaincontaining E3 ligase family involved in the regulation of immunological response and cancer development 25, 26, 27 . Finally, HOIP, a RBR E3 ubiquitin ligase and member of the LUBAC (linear ubiquitin chain assembly complex). As part of the LUBAC complex, HOIP is involved 115 in the regulation of important cellular signalling pathways that control innate immunity and inflammation through nuclear factor (NF)-kB activation and protection against tumour necrosis factor α (TNFα)-induced apoptosis 28, 29 . HOIP is the only known E3 ligase generating linear ubiquitin chains 30 . Because of that, fluorescent assays using C-terminally or N-terminally labelled ubiquitin species cannot be used to form linear chains. 120
To determine MDM2, ITCH and HOIP auto-ubiquitylation reaction rate and the linearity range we followed the consumption of mono-ubiquitin over time with increasing starting amount of mono-ubiquitin. We matched MDM2, ITCH and HOIP with E2 conjugating enzymes as reported in literature: MDM2 and ITCH were incubated with E2D1 (UbcH5a) 31 while HOIP was used in combination with UBE2L3 (UbcH7) 28 . Briefly, the in vitro ubiquitylation reaction 125 consisted of 1 mM ATP, 12.5, 6.25 and 3.125 µM ubiquitin (Ub), 50 nM E1, 250 nM E2 and 250 or 500 nM E3 ligase enzyme at 37°C for 30 min in a total volume of 5 µl (Figure 1A) .
Reactions were started by addition of Ub and terminated by addition of 2.5 µl of 10% (v/v) trifluoroacetic acid (TFA). 1.05 µl of each reaction was then spiked with 300 nl (4 µM) of 15 Importantly, the use of 15 N ubiquitin as internal standard allowed us not only to avoid spot-tospot and shot-to-shot variability in MALDI ionization 32 , but also it allowed us to keep track of 135 the amount of mono-ubiquitin "consumed" during the assay. Overall, this setup allowed us to achieve very high precision, accuracy and reproducibility of measurements.
In our experimental conditions, Ub-consumption relied on the presence on an E3 ligase as we did not observe a significant reduction in the ubiquitin level within the negative controls ( Figure   1B) , where only E1 activating enzyme and E2 conjugating enzyme were present. We found 140 that the optimal concentrations for the enzymes used were in the nanomolar range (250 nM for HOIP, 500 nM for ITCH and 500 nM for MDM2). As expected, we observed that Ub consumption is dose and enzyme dependent (Figure 1B, Supplementary Fig. 1) . Reaction rates were related to Ub concentration ( Supplementary Table 1 ) and different enzymes showed different rates of ubiquitin consumption (Figure 1B) . 145
The well-established E2-E3 auto-ubiquitylation assays followed by SDS-Page and western blot analysis provided similar results and we observed that the time dependent disappearance of Ub is comparable using both techniques ( Figure 1C) . Moreover, while substrate and enzyme concentrations are comparable to Western Blot based approaches, the reaction volume (5 µl) is smaller than most of the antibody-based approaches currently reported in 150 literature 33 . specific Lys residues with ubiquitin is another intrinsic property of many E2 enzymes. Early studies showed that at high concentrations, E2 enzymes can synthesize ubiquitin chains of a 160 distinct linkage or undergo auto-ubiquitylation even in the absence of an E3 36 , albeit at lower transfer rates 34 . This characteristic has been exploited for the generation of large amounts of different ubiquitin chain types in vitro 37 .
Determining in vitro activities of E2 enzymes
As control for E2 enzyme mono or multi-ubiquitylation or E2-dependent ubiquitin chain assembly, we firstly assessed which E2 conjugating enzymes in our panel were able to 165 consume ubiquitin even in absence of a partner E3 ligase. Utilizing the MALDI TOF E2-E3 assay, we systematically tested 27 recombinantly expressed E2 conjugating enzymes ( Supplementary Table 2 ) for their ability to process ubiquitin either by the formation of polyubiquitin chains or by auto-ubiquitylation at different concentrations (250 nM, 500 nM and 1 µM). We found that the UBE2Q1 and UBE2Q2 were able to consume ubiquitin even in 170 absence of a specific E3 ligase at 250 nM after 45 min incubation time and almost completely exhausting the starting ubiquitin amount after 2h of incubation (Figure 2 ). UBE2O and UBE2S are able to consume ubiquitin when present at a starting concentration of 500 nM with consumption being evident from 90 min onwards. Interestingly, UBE2Q1, UBE2Q2 and UBE2O 38, 39, 40 are E2 conjugating enzymes characterized by an unusually high molecular 175 mass compared to other E2 enzymes: in particular UBE2O has been reported as an E2-E3 hybrid which might explain its ability to form ubiquitin chains in absence of an E3 ligase. Most of the E2 conjugating enzymes showed ubiquitin-consuming activity once their concentration was increased to 1 µM. Interestingly, UBE2D1 and UBE2L3 do not show any ligase activity even at 1 µM, making these E2 conjugating enzymes the perfect candidates for inhibitor 180 screening of E3 ligases as all ubiquitin consuming activity in an assay will be down to E3 activity. Our results demonstrate that the E2-E3 MALDI TOF assay has the potential to be employed for measuring E2 in vitro activity and therefore can be employed for screening inhibitors against those E2 enzymes that possess intrinsic ubiquitin ligase activity in vitro.
Determining E2/E3 active pairs 185
Any given E3 ligase cooperates with specific E2 enzymes in vivo. However, it is still difficult to predict which E2/E3 enzyme pair would be functional. Determining E2/E3 specificity is paramount to set up in vitro ubiquitylation assays and to perform inhibitor screens against E3 ligases. Using the E2/E3 MALDI TOF assay, we investigated the activity of MDM2, ITCH and HOIP throughout eight time points when incubated with any of 27 ubiquitin E2 enzymes, 190 covering the majority of the reported classes/families (Figure 3) . We arbitrarily defined "fully active" pairs any E2-E3 couple that completely depleted the mono-ubiquitin starting amount after 2 hours incubation time. The UBE2D family is reported in literature as being able to productively interact with MDM2 41 , ITCH 33 and HOIP 42 . Our data showed that UBE2D1 and UBE2D2, also known as UBCH5a and UBCH5b, were fully active with all the E3 ligases under 195 investigation confirming the promiscuous activity of this class of E2 enzymes that was previously reported in the literature 33, 41, 42 . The UBE2E family was only partially active against the E3s ligases of interest. The well-characterized human E2L3 (or UBCH7) showed activity with HOIP and ITCH, confirming the already reported UBCH7 ability of functioning with both HECT and RBR E3 families 43, 44 . Taken together these results demonstrate that the E2/E3 200 MALDI TOF assay is suitable for determining E2 specificity towards their cognate E3 enzymes in a high-throughput fashion.
Assessing potency and selectivity of E2/E3 inhibitors
We next evaluated whether the MALDI TOF E2/E3 assay had potential to assess the potency and selectivity of E2/E3 inhibitors. As proof-of-concept, we tested 5 inhibitors that had 205 previously been reported to inhibit E1, E2 or E3 ligases: PYR41 45 , Bay117082 46 , Gliotoxin 47 , Nutlin3A 48 and Clomipramine 49 . We also tested PR619 50 a broad spectrum, alkylating DUB inhibitor that we hypothesised would also inhibit other enzymes with active site cysteines, such as E1/E2 enzymes and E3 ligases. PYR41 is a specific and cell permeable inhibitor of E1 ubiquitin loading but does not directly affect E2 activity 45 . Bay117082, initially described as 210 inhibitor of nuclear factor κB (NF-κB) phosphorylation, has been shown to inactivate the E2conjugating enzymes Ubc13 (UBE2N) and UBCH7 (UBE2L3) as well as the E3 ligase LUBAC (of which HOIP is part) 46 . Gliotoxin is a fungal metabolite identified as a selective inhibitor of HOIP through a FRET-based HTS assay 47 . Nutlin 3A is a MDM2-p53 interaction inhibitor, able to displace p53 from MDM2 with an IC50 in the 100 to 300 nM range 51 . However Nutlins are 215 not reported to be able to inhibit MDM2 auto-ubiquitylation. Clomipramine is a compound reported as able to block ITCH Ub transthiolation in an irreversible manner, achieving complete inhibition at 0.8 mM 49 . Performing IC50 inhibition curves using the MALDI TOF E2/E3 assay (Figure 4, Supplementary Table 3 ), we could show that PYR41 inhibited both HOIP and ITCH at IC50s of 5.4 µM and 11.3 µM, respectively. Bay117082 also strongly 220 inhibited HOIP and ITCH with an IC50 of 2.9 µM and 25.9 µM, respectively. It is important to underline that the IC50 calculation maybe be affected by the content in DTT/TCEP and or βmercaptoethanol as these compound might also react with compounds that are highly reactive towards thiol groups. Gliotoxin showed an IC50 of 2.8 µM against HOIP and 30.61 µM against ITCH but it did not inhibit MDM2. As expected, Nutlin 3A did not show any inhibitory activity 225 towards MDM2, ITCH or HOIP as it was designed as an interaction inhibitor. We found that Clomipramine acted as a weak inhibitor for ITCH with an IC50 of 503.4 µM but it did not affect MDM2 or HOIP. Our results demonstrate that the MALDI TOF E2-E3 assay is suitable for comparing drug potency through IC50 determination.
230
E2/E3 assay by MALDI TOF is suitable for HTS
Having established that the E2/E3 MALDI TOF assay can be used to assess the specificity and potency of inhibitors, we explored its suitability for high-throughput screening. It is important to underline that, because of the nature of the assay, inhibitors of either E1 or E2, which both contain active site cysteines 47, 49 that form thioester intermediates with ubiquitin 235 may be identified as hits. We tested a library of 1430 FDA approved compounds from various commercial suppliers with validated biological and pharmacological activities at 10 µM final.
None of the compounds present in the library are known for specifically targeting MDM2, ITCH or HOIP. The assay was performed supplying ATP in excess (1 mM) to reduce the likelihood of identifying ATP analogues as inhibitors of these enzymes. 240
The screens against the three different E3 ligases, expressed as percentage effect ( Supplementary Table   4 ). These scores provide a measure for the suitability of screening assays; HTS assays that provide Z' scores > 0.5 are generally considered robust. We defined as a positive hit a compound whose potency ranked above the 50% residual activity threshold. Overall, we 245 identified 9 compounds reporting inhibition rates >50% against the E3 ligases of interest.
Candesartan Cilexetil was the only compound able to inhibit MDM2 activity more than 50% (see Table 1 ). With regard to HOIP screening, six compounds were identified as potential inhibitors: Bendamustine, Moclobemide, Ebselen, Cefatrizine, Fluconazole and Pyrazinamide.
The ITCH inhibitor screening identified two positive hits: Hexachlorophene and Ethacrynic 250 Acid. Hexachlorophene is an organochloride compound once widely used as a disinfectant. It acts as an alkylating agent thus resulting in the wide and not specific inhibition of E3 ligases: this explains why this compound results as a weak inhibitor of MDM2 as well. Ethacrynic acid is a diuretic compound 52 and a potent inhibitor of glutathione S-transferase with intrinsic chemical reactivity toward sulfhydryl groups 53 that might explains its ranking as positive hit in 255 our assay when tested against both MDM2 and ITCH.
Overall, our results demonstrate that the E2/E3 MALDI TOF assay can be employed to screen large compound libraries against E3 ligases belonging to different families for the identification of new inhibitors.
Validation of positive hits 260
To validate the results obtained from the HTS we performed IC50 determination of compounds with the highest inhibitor potency in the single point screening. Candesartan Cilexitel, an angiotensin II receptor antagonist, inhibited MDM2 with an IC50 of 8.9 µM (Figure 6A) . Best hit was Bendamustine, a nitrogen mustard used in the treatment of chronic lymphocytic leukemia and lymphomas. It belongs to the family of alkylating agents. Bendamustine ranked 265 as the compound with the highest inhibition score against HOIP while it did not significantly affect MDM2 and ITCH activities. We confirmed that Bendamustine selectively inhibited HOIP at an IC50 = 6.4 µM while ITCH and MDM2 showed considerably higher IC50s (113 and 76.8 µM respectively) ( Figure 6B) . Bendamustine retained its inhibition power when HOIP was paired with UBE2D1 as conjugating enzyme (Supplementary Figure 3) suggesting that the 270 compound binds preferentially to HOIP. This shows that the MALDI TOF E2/E3 ligase assay can be used to identify selective inhibitors from a high-throughput screen.
Discussion
The ubiquitin system has in recent years become an exciting area for drug discovery 54 applicability of fluorescence-based techniques such as FRET is dependent on being able to get FRET donors and acceptors in the right distance and the fluorescent label might affect inhibitor binding. To address these issues, we have developed a sensitive and fast assay to quantify in vitro E2/E3 enzyme activity using MALDI TOF MS. It builds on our DUB MALDI TOF assay 32 , which has enabled us to screen successfully for a number of selective DUB 295 inhibitors 56, 57, 58 , and adds to the increasing number of drug discovery assays utilising labelfree high-throughput MALDI TOF MS. Apart from E2/E3 enzymes and DUBs 32 , highthroughput MALDI TOF MS has now successfully been used for drug discovery screening of protein kinases 59 , histone demethylases and acetylcholinesterases 60 as well as histone lysine methyltransferases 61 . 300 Unlike other current assays, all these label-free MALDI TOF MS methods use unmodified substrates, such as mono-ubiquitin. The advantages compared to fluorescence or antibodybased high-throughput assays is the ability to work with enzymes without the previous development of specific chemical/fluorescent probes as well as the reduced consumable costs for the assay as no antibodies are required. Moreover, because of the sensitivity of current 305 MALDI TOF mass spectrometers, all enzymes are usually kept at low concentrations thereby significantly reducing the amounts and cost per assay.
In the context of E3 ligase drug discovery, it is critical to identify the appropriate E2/E3 substrate pairing to ensure the development and use of the most physiologically relevant screening assay. There have been many reports of limited E2/E3 activity profiling with a small 310 number of E2 and E3 enzymes using ELISA-based assays, structural-based yeast two-hybrid assays and Western blot 33, 41, 42 . All of these approaches are time consuming, require large amounts of reagents and are difficult to adapt for HTS. We have successfully used our E2/E3 MALDI TOF assay to identify active E2/E3 pairings which could then be further characterized using our HTS screen. The "E2 scan" was quickly and easily adapted, collecting data of three 315 E3 enzymes against 29 E2 enzymes at eight time-points in one single experiment. Moreover, after identification of the right E2/E3 pairs, we applied the MALDI TOF E2/E3 assay to determine inhibition rates and the IC50 of small molecule inhibitors. In a proof-of-concept study, we performed a HTS for inhibitors of three E3 ligases. The MALDI TOF analysis speed of 1.3 seconds per sample (~35 minutes per 1536 well plate) and low sample volumes 320 (reaction volume 5 μL / MALDI deposition 250 nL) make the E2/E3 MALDI TOF assay comparable to other fluorescence/chemical probe based technologies. Automatic sample preparation, MALDI TOF plate spotting and data collection allowed us to quickly analyse thousands of compounds through the use of 1536-sample targets. The assay successfully identified Bendamustine as a nnovel small molecule inhibitor for HOIP, an attractive drug 325 target for both inflammatory disease and cancer 30, 62, 63, 64 . Bendamustine, a nitrogen mustard, shows likely very high reactivity against a range of targets in the cell including its intended target DNA. However, it is surprising that it shows a 12-fold and 18-fold higher activity against HOIP than against ITCH and MDM2, respectively, suggesting that there is possibly a structural effect and some selectivity can be reached between different E3 ligases. As changes of the 330 E2 enzyme did not change the inhibition of HOIP by Bendamustine, it also shows that E1 and E2 conjugating enzymes were not affected. While this is just a proof-of-concept study characterising E2/E3 activity and identifying inhibitors in an in vitro system, follow-up studies will need to verify results in cellular and ultimately in vivo models.
In conclusion, we present here a novel screening method to assay E2/E3 activity with high 335 sensitivity, reproducibility and reliability, which is able to carry out precise quantified measurements at a rate of ~1 s per sample spot. Using physiological substrates, we showed proof-of concept for three E3 ligases that are attractive drug targets. Considering the speed, low consumable costs and the simplicity of the assay, the MALDI TOF E3 ligase assay will serve as a sensitive and fast tool for screening for E3 ligase inhibitors. 340
Materials and Methods
Materials
Ubiquitin monomer, BSA, Tris, DTT, Clomipramine and Gliotoxin were purchased from Sigma-Aldrich. MALDI TOF MS materials (targets, matrix and protein calibration mixture) were 345 purchased from Bruker Daltonics (Bremen, Germany). PYR41 and Nutlin3A compounds were kindly provided by Sara Buhrlage, PhD (Dana-Farber Cancer Institute). Plasmids generated at the University of Dundee for the present study are available to request 385 on our reagents website (https://mrcppureagents.dundee.ac.uk/). For E2 activity assays, we pre-incubated the Ube1 activating enzyme (100 nM) with 27 E2 405 conjugating enzymes at 1000 nM, 500 nM and 250 nM and stopped the reaction with 2% final TFA at different time points.
E1, E2, ITCH and HOIP E3 enzyme expression and purification
E1/E2/E3 assay
Compound Library spotting and inhibitor screening
We used a library of 1430 FDA approved compounds from various commercial suppliers with 410 validated biological and pharmacological activities. The performance of the assay on each screening plate was evaluated using internal controls to determine robust Z' values, which were calculated as follows:
Where the means ( ) and standard deviations ( ) of both the positive (p) and negative (n) controls are reported. 
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